Cargando…
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
Autores principales: | Pichiorri, Flavia, Palmieri, Dario, De Luca, Luciana, Consiglio, Jessica, You, Jia, Rocci, Alberto, Talabere, Tiffany, Piovan, Claudia, Lagana, Alessandro, Cascione, Luciano, Guan, Jingwen, Gasparini, Pierluigi, Balatti, Veronica, Nuovo, Gerard, Coppola, Vincenzo, Hofmeister, Craig C., Marcucci, Guido, Byrd, John C., Volinia, Stefano, Shapiro, Charles L., Freitas, Michael A., Croce, Carlo M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413319/ https://www.ncbi.nlm.nih.gov/pubmed/28104811 http://dx.doi.org/10.1084/jem.2012095001172017c |
Ejemplares similares
-
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2013) -
Circulating miRNA markers show promise as new prognosticators for multiple myeloma
por: Rocci, A, et al.
Publicado: (2014) -
Photoelectron Photoion Coincidence Spectroscopy of NCl(3) and NCl(2)
por: Gerlach, Marius, et al.
Publicado: (2021) -
NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs
por: Sheetz, Tyler, et al.
Publicado: (2020) -
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)